Metabolic alterations and targeted therapies in prostate cancer.
about
Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic AgentsA novel approach to the discovery of anti-tumor pharmaceuticals: searching for activators of liponecrosisHuman Prostate Cancer Hallmarks MapMolecular pathways involved in prostate carcinogenesis: insights from public microarray datasetsMetformin therapy and the risk of colorectal adenoma in patients with type 2 diabetes: A meta-analysisInhibition of the LKB1-AMPK pathway by the Epstein-Barr virus-encoded LMP1 promotes proliferation and transformation of human nasopharyngeal epithelial cellsA metabolic perturbation by U0126 identifies a role for glutamine in resveratrol-induced cell death.Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer.Novel nuclear localization of fatty acid synthase correlates with prostate cancer aggressivenessMonoacylglycerol lipase promotes metastases in nasopharyngeal carcinoma.Dietary energy balance modulates prostate cancer progression in Hi-Myc miceStromal proteome expression profile and muscle-invasive bladder cancer research.High-calorie diet exacerbates prostate neoplasia in mice with haploinsufficiency of Pten tumor suppressor geneCuration of the Mammalian Palmitoylome Indicates a Pivotal Role for Palmitoylation in Diseases and Disorders of the Nervous System and Cancers.Lipin-1 regulates cancer cell phenotype and is a potential target to potentiate rapamycin treatmentButein induces apoptosis and inhibits prostate tumor growth in vitro and in vivo.Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patientsEarly growth response 1 and fatty acid synthase expression is altered in tumor adjacent prostate tissue and indicates field cancerization.Dysregulated lipid metabolism in cancer.PPARγ isoforms differentially regulate metabolic networks to mediate mouse prostatic epithelial differentiation.Basic aspects of tumor cell fatty acid-regulated signaling and transcription factors.Association of fatty-acid synthase polymorphisms and expression with outcomes after radical prostatectomy.Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses.Androgens promote prostate cancer cell growth through induction of autophagy.Caveolin-1-LRP6 signaling module stimulates aerobic glycolysis in prostate cancerAssociation between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categoriesCancer prevention and therapy through the modulation of the tumor microenvironment.High blood sugar levels significantly impact the prognosis of colorectal cancer patients through down-regulation of microRNA-16 by targeting Myb and VEGFR2.Influence of free fatty acids on glucose uptake in prostate cancer cellsThe metastasis inducer CCN1 (CYR61) activates the fatty acid synthase (FASN)-driven lipogenic phenotype in breast cancer cells.Activated lymphocytes as a metabolic model for carcinogenesis.Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells.A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis.Cancer biology and genomics: translating discoveries, transforming pathology.Lipids and prostate cancer.Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer.The fat side of prostate cancer.18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients.Long-term effects of nanoparticles on nutrition and metabolism.
P2860
Q26740567-3AB55920-9230-453B-8027-609951E760ADQ26774351-ADA0CFBD-DAB8-4A58-82C0-3CC69905EA62Q26779590-039EE9EE-9031-470C-9414-EA29D90A05E3Q27990300-AE364AF5-FCD1-4F86-BCD8-563BCBE3E619Q28072501-CF5E9DAF-9FA0-4812-8D64-9543D0CB5422Q29303134-02CECEEA-2092-484D-BC95-443A3D014DBFQ30423585-3EE94D91-DE0D-4B73-8D39-99E0F69BCE8EQ33761619-B423E7E1-4031-4154-94AC-D26D56985EC4Q33921635-7C029B28-D308-4BAF-8EEE-D2DEA4F5452EQ33978062-EC7A6727-1268-41B0-81C0-ABF8BA01560EQ34028928-8B7617D6-165E-4EF9-AC77-0A3BC45244D1Q34227830-CC000343-ADEA-4212-A8FE-17ED0E834200Q34392967-42E6BE15-7CA3-44D9-89DB-28D096F332D8Q35113473-1D2121DD-21AD-4588-B161-8F56C85355A5Q35746623-2919A6ED-F720-46DE-BADB-F9FE9D98DBC6Q35793782-323A6EBD-CA32-4184-844D-6CB22C5A27E8Q35884596-565DB33C-396E-44A5-956C-15B9FDE1BBC2Q35898302-7EACD17E-5EC2-4D5C-B10A-85597ED4D358Q35923141-8D255BBC-0339-4667-AACD-F4ED6C01477AQ36198689-8963819D-62DA-44FE-A84C-BC9E2D2D7BBFQ36211459-E0F799E8-40EF-44D3-B214-A323EBDAE690Q36294936-47B0A535-8BC7-4EA9-9EA9-68BC38D3AA79Q36570819-77C1FB75-5797-47B1-8737-4122F54891EAQ36584255-C436BFEF-1A92-4B0B-94C9-A7A82A698175Q36932530-3A4B55FA-4316-42B4-8A4F-DB8DB064A250Q36944221-2ADC47D5-C19E-4162-B8F1-2D8D225616D6Q37045608-B528BF66-7BE8-4550-A0C5-AE9FAA3F039CQ37058267-A0E52B31-1880-49A9-BCEF-4178D7C30056Q37109882-C0EDBF77-E537-4D62-B545-2D3C1D855591Q37122861-386420C4-4E43-4F34-9512-8D480FC84E70Q37298189-935380EF-3EC8-4BA8-BF39-2F23ECCB4048Q37326607-26A1E3DC-2EEE-49A4-B885-6050BF5811A6Q37706959-EE68AD83-21CE-4802-A8E2-1CE068278727Q37710823-4FE192BC-5737-49A6-A988-CBFBBA110BE7Q37810056-142E443C-CF32-4936-9016-497887E3195BQ38002682-A54364E8-7085-4042-8D85-55EB2418F561Q38073079-A7168D8B-B3DE-40E8-B256-FBE69101894BQ38096735-923D8560-C031-4372-874C-6C9F469096C0Q38098441-25ABC6FA-5468-456B-8D6F-79B62BFDDB6EQ38212102-547BCEA5-763F-467C-AD4A-6D4CADC64AAC
P2860
Metabolic alterations and targeted therapies in prostate cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Metabolic alterations and targeted therapies in prostate cancer.
@ast
Metabolic alterations and targeted therapies in prostate cancer.
@en
type
label
Metabolic alterations and targeted therapies in prostate cancer.
@ast
Metabolic alterations and targeted therapies in prostate cancer.
@en
prefLabel
Metabolic alterations and targeted therapies in prostate cancer.
@ast
Metabolic alterations and targeted therapies in prostate cancer.
@en
P2860
P356
P1476
Metabolic alterations and targeted therapies in prostate cancer.
@en
P2093
Giorgia Zadra
Richard Flavin
P2860
P304
P356
10.1002/PATH.2809
P50
P577
2010-11-16T00:00:00Z